Compound ID | 2855
Class: Antimicrobial peptide
| Agent Type: | Natural product; |
| Spectrum of activity: | Gram-positive & Antimycobacterial |
| Mechanism of action: | Unknown |
| Target Pathogen: | Active against Staphylococcus aureus, Mycobacterium bovis, and multidrug- and extensively-drug-resistant Mycobacterium tuberculosis |
| Description: | Natural product from Streptomyces sp., MST-11508; shows cytotoxicity to Hep2G cells at IC50 56 uM vs antimycobacterial effect at IC50 0.6-3.1 uM ; an optimised synthetic wollamide B1 with lower mammalian cytotoxicity compared to natural product had been reported; shows synergistic effect with pretomanid, delamanid, ethambutol, and para-aminosalicylic acid; a cyclic hexapeptide |
| Institute where first reported: | Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia |
| Year first mentioned: | 2014 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/102341742 |
| Guide to Pharmacology: | wollamide B |
| Citations: |
|